CSL Behring verwerf AMT-061, Hem B gentherapie in fase 3-verhoor

CSL Behring verwerf AMT-061, Hem B gentherapie in fase 3-verhoor

CSL Behring

Image

Please enable the javascript to submit this form

Ondersteun deur opvoedkundige toekennings van Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics en uniQure, Inc.

Noodsaaklike SSL